TNFRSF4 and neoplasm: Compared with the HVJ-E/control antibody treatment, gene set enrichment analysis revealed that HVJ-E/OX40 antibody activated anti-tumor immune responses, such as defense response to virus and response to IFN-β, in most of the clusters (Figure 5C).